Aarti Drugs Intrinsic Value
AARTIDRUGS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹435.60 | ₹348.48 - ₹522.72 | +10.9% | EPS: ₹19.80, Sector P/E: 22x |
| Book Value Method | asset | ₹300.88 | ₹270.79 - ₹330.97 | -23.4% | Book Value/Share: ₹150.44, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹574.07 | ₹516.66 - ₹631.48 | +46.1% | Revenue/Share: ₹287.03, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹362.99 | ₹326.69 - ₹399.29 | -7.6% | EBITDA: ₹336.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹328.48 | ₹262.78 - ₹394.18 | -16.4% | CF Growth: 12.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹126.72 | ₹114.05 - ₹139.39 | -67.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹305.91 | ₹275.32 - ₹336.50 | -22.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹237.36 | ₹213.62 - ₹261.10 | -39.6% | ROE: 13.1%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹258.88 | ₹232.99 - ₹284.77 | -34.1% | EPS: ₹19.80, BVPS: ₹150.44 |
Want to compare with current market value? Check AARTIDRUGS share price latest .
Valuation Comparison Chart
AARTIDRUGS Intrinsic Value Analysis
What is the intrinsic value of AARTIDRUGS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aarti Drugs (AARTIDRUGS) is ₹305.91 (median value). With the current market price of ₹392.80, this represents a -22.1% variance from our estimated fair value.
The valuation range spans from ₹126.72 to ₹574.07, indicating ₹126.72 - ₹574.07.
Is AARTIDRUGS undervalued or overvalued?
Based on our multi-method analysis, Aarti Drugs (AARTIDRUGS) appears to be trading above calculated value by approximately 22.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.64 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.88 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 13.1% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.01x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Aarti Drugs
Additional stock information and data for AARTIDRUGS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹245 Cr | ₹163 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹359 Cr | ₹247 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹133 Cr | ₹51 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹70 Cr | ₹-5 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹155 Cr | ₹119 Cr | Positive Free Cash Flow | 8/10 |